Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 Next >
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
Tickers ALVO
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
Tickers ALVO
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Secures Financing Facilities of Approximately $136 Million
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.